Illumina, Inc. (LON: 0J8Z)

Market Cap	18.07B
Revenue (ttm)	3.28B
Net Income (ttm)	-1.18B
Shares Out	n/a
EPS (ttm)	-7.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,943
Average Volume	2,612
Open	139.73
Previous Close	140.20
Day's Range	139.32 - 145.41
52-Week Range	89.21 - 232.20
Beta	1.13
RSI	53.93
Earnings Date	Feb 7, 2025

About Illumina

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regio...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 10,640
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J8Z

Financial Performance

In 2023, Illumina's revenue was $4.50 billion, a decrease of -1.75% compared to the previous year's $4.58 billion. Losses were -$1.16 billion, -73.64% less than in 2022.

Financial numbers in USD